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Abstract 
 Microcephalic primordial dwarfism (MPD) is a group of rare single-gene 
disorders characterised by extreme reduction in brain and body size from 
early development onwards. Proteins encoded by MPD-associated genes 
play important roles in fundamental cellular processes, notably genome 
replication and repair. Here we report identification of four MPD individuals 
with biallelic variants in DNA2, which encodes an ATP-dependent 
helicase/nuclease involved in DNA replication and repair. We demonstrate 
that the two intronic variants (c.1764-38_1764-37ins(53) and c.74+4A>C) 
found in these individuals substantially impair DNA2 transcript splicing. 
Additionally we identify a missense variant (c.1963A>G), affecting a residue of 
the ATP-dependent helicase domain that is highly conserved between 
humans and yeast, with the resulting substitution (p.Thr655Ala) predicted to 
directly impact ATP/ADP binding by DNA2. Our findings support pathogenicity 












of these variants as biallelic hypomorphic mutations, establishing DNA2 as an 
MPD-disease gene. 
Graphical Abstract 
We report identification of biallelic DNA2 variants in four unrelated individuals with 
Microcephalic primordial dwarfism (MPD). Using cellular splicing assays and 
molecular modelling we provide evidence that these variants result in partial loss of 
function of DNA2, an ATP-dependent helicase/nuclease with functions in DNA 
replication and repair, supporting their pathogenicity and establishing DNA2 as an 
MPD-disease gene. 
 
Keywords: DNA2, growth, microcephalic primordial dwarfism, DNA 
replication, DNA repair  
Main text 
Microcephalic primordial dwarfism (MPD) is an umbrella term for a 
group of rare monogenic disorders of extreme growth failure, characterised by 
marked microcephaly and short stature. MPD has been operationally defined 












in terms of both occipito-frontal circumference (OFC) and height being at least 
4 standard deviations (SD) below the age- and sex-matched population mean 
(Faivre et al., 2002; Klingseisen & Jackson, 2011), although less restrictive 
criteria to encompass individuals with milder growth restriction have also been 
used (Shaheen et al., 2018). MPD encompasses several phenotypically-
distinct Mendelian disorders, such as Seckel syndrome (Majewski, Goecke, & 
Opitz, 1982; Seckel, 1960), microcephalic osteodysplastic primordial dwarfism 
type 1 and type 2 (Majewski, Ranke, Schinzel, & Opitz, 1982; Majewski, 
Stoeckenius, Kemperdick, & Opitz, 1982) and Meier-Gorlin syndrome (Gorlin, 
Cervenka, Moller, Horrobin, & Witkop, 1975). A phenotype continuum 
between primary microcephaly (MCPH) and MPD is also established for a 
number of genes (Shaheen et al., 2018; Verloes, Drunat, Gressens, & 
Passemard, 1993). 
Proteins encoded by MPD disease genes participate in essential 
cellular processes, including DNA replication (Bicknell, Bongers, et al., 2011; 
Bicknell, Walker, et al., 2011; Burrage et al., 2015; Fenwick et al., 2016; 
Guernsey et al., 2011; Logan et al., 2018; Vetro et al., 2017), DNA damage 
response signalling and DNA repair (Harley et al., 2016; Murray et al., 2014; 
Murray et al., 2015; O'Driscoll, Ruiz-Perez, Woods, Jeggo, & Goodship, 2003; 
Ogi et al., 2012; Qvist et al., 2011; Reynolds et al., 2017). Collectively, 
variants in these genes are thought to cause disease by prolonging the cell 
cycle, with reduced cell proliferation resulting in a smaller number of cells 
throughout the body and brain, and therefore a smaller person (Klingseisen & 
Jackson, 2011).  












The ATP-dependent helicase/nuclease DNA2 is a multi-functional 
enzyme, involved in various aspects of DNA replication and repair, including 
Okazaki fragment maturation during lagging strand synthesis (Ayyagari, 
Gomes, Gordenin, & Burgers, 2003; Bae, Bae, Kim, & Seo, 2001; Gloor, 
Balakrishnan, Campbell, & Bambara, 2012), DNA end resection during 
double-strand break repair (Cejka et al., 2010; Karanja, Cox, Duxin, Stewart, 
& Campbell, 2012; Nimonkar et al., 2011; Niu et al., 2010; Sturzenegger et al., 
2014), degradation of reversed replication forks to promote replication restart 
after genotoxic stress (Thangavel et al., 2015) and regulation of replication 
checkpoint activation (Duxin et al., 2012). Additionally, DNA2 has been 
implicated in mitochondrial DNA replication and repair (Duxin et al., 2009; 
Zheng et al., 2008). Most of the cellular functions of DNA2 have been 
attributed to its nuclease activity, whereas the role of DNA2 helicase activity 
long remained unclear. However, recently it was shown to act as an ATP-
dependent translocase to promote rapid DNA degradation during DNA end 
resection (Levikova, Pinto, & Cejka, 2017; Miller et al., 2017). Unsurprisingly, 
because of its importance for genome replication and stability, DNA2 is 
essential for mammalian embryonic development (Lin et al., 2013). A 
homozygous intronic DNA2 variant was previously reported as the likely 
causal variant for two related individuals diagnosed clinically with Seckel 
syndrome. This variant was shown to cause aberrant splicing and reduced 
DNA2 protein levels in patient cells, with cellular phenotypes rescued by 
transient wildtype DNA2 expression (Shaheen et al., 2014). Here, we report 
the identification of additional biallelic DNA2 (NM_001080449.2; MIM# 
601810) variants in four unrelated MPD patients. Using cellular splicing 












assays and molecular modelling we provide evidence that these result in 
partial loss of function of the essential DNA replication/repair protein it 
encodes. Our work, alongside the findings of Shaheen et al. (2014), therefore 
establishes a causal link between DNA2 deficiency and impaired growth. 
From WES sequencing of 192 MPD patients without a molecular 
diagnosis, we identified three unrelated patients (P1, P3 and P4) with biallelic 
variants in DNA2 (Fig. 1A, Supp. Table S1 and S2), with a fourth 
phenotypically similar patient (P2) identified through targeted re-sequencing of 
DNA2 in our cohort. No likely causative variants in other genes were evident 
in WES datasets from P1, P3 and P4 (Supp. Table S3 and S4). The two 
novel intronic variants (NM_001080449.2:c.1764-38_1764-37ins(53) and 
NM_001080449.2:c.74+4A>C) and single missense variant 
(NM_001080449.2:c.1963A>G, p.Thr655Ala) were validated using Sanger 
sequencing (Fig. 1B). Parents of the affected individuals were heterozygous 
for these variants, and segregation in unaffected siblings from P1 and P3 
consistent with an autosomal recessive inherited disorder. None of the 
variants were present in the gnomAD (genome aggregation) database (Lek et 
al., 2016), establishing these alleles to be very infrequent in the general 
population, in keeping with a rare Mendelian disorder. All variants were 
submitted to the LOVD Global Variome database 
(https://databases.lovd.nl/shared/genes/DNA2). 
The patients exhibited severe microcephaly with OFC ranging from 
−5.7 SD to −9.6 SD, as well as markedly reduced height, ranging from −4.6 
SD to −11.1 SD (Supp. Table S1, Fig. 1C). Three out of four patients with 












DNA2 variants were noted to have prominent, large upper incisors and a high 
frontal hairline, however a common facial gestalt was not otherwise apparent 
(Supp. Table S2, Fig. 1D). No significant health problems were noted, aside 
from P3 who had severe thoracic kyphoscoliosis and recurrent chest 
infections (Supp. Table S2). All had normal intellectual development, with P3 
and P4 now adolescents and P2 healthy when last met aged 46. Normal 
cognition, lack of a sloping forehead and proportionate OFC to height 
reduction led us to clinically classify these patients as MPD, rather than 
Seckel syndrome. Given the overlapping clinical phenotypes, we concluded 
that these variants were likely to be pathogenic, despite their predominantly 
intronic nature, and we next investigated the consequences of these variants 
on DNA2 mRNA splicing. 
P1 and P2, not knowingly related, were homozygous for the same 
variant, a 53 bp insertion in the middle of the small (78 bp) intron 11 of DNA2 
(c.1764-38_1764-37ins(53), Fig. 1A, Supp. Table S1). SpliceSiteFinder-like, 
MaxEntScan, and Human Splicing Finder algorithms (Alamut Visual) 
predicted the creation of a new splice donor site after the first four bases of 
inserted sequence, suggesting that DNA2 transcript splicing could be affected 
by this variant. As patient-derived cell lines were not available and attempts to 
generate a lymphoblastoid cell line from P1 peripheral blood leukocytes 
(PBLs) were not successful, we employed a minigene-based splicing assay to 
study the consequences and establish the pathogenicity of this variant. 
Minigene splicing reporters (Singh & Cooper, 2006) containing the genomic 
region covering DNA2 exon 11 to exon 13 from a healthy control and P1 were 
constructed (Fig. 2A). While the splicing control with a disrupted acceptor 












splice site of intron 11 (c.1764-1G>A) demonstrated complete abrogation of 
correct splicing, the c.1764-38_1764-37ins(53) variant resulted in marked, but 
partial loss of correct splicing (Fig. 2B). DNA2 transcript analysis using RNA 
isolated from P1 PBLs also demonstrated altered splicing (Fig. 2C), 
confirming that partial loss of correct DNA2 splicing occurs as a result of this 
intronic variant. Capillary sequencing of RT-PCR products demonstrated 
correctly spliced mRNA for the wild-type control, with DNA2 exons 11, 12 and 
13 included (Fig. 2B-D), while for P1, the majority contained full-length exons 
11 and 13, but lacked exon 12 (Fig. 2B-D), in keeping with the c.1764-
38_1764-37ins(53) insertion causing substantial skipping of exon 12. Absence 
of exon 12 causes a frameshift leading to a premature termination codon in 
exon 13 (p.Ser588ArgfsTer4), which would promote degradation of such 
transcripts by nonsense-mediated decay and/or lead to the translation of a 
severely truncated protein missing the majority of the helicase domain, 
including the ATP binding site. Both would result in marked reduction of 
cellular levels of functional DNA2 protein.  
P4 was homozygous for a putative splice site variant in intron 1 
(c.74+4A>C) (Fig. 1A, Supp. Table S1), predicted to be potentially 
deleterious (CADD score = 16.4). Furthermore, splice prediction analysis 
suggested that this variant would weaken the donor splice site of intron 1, and 
therefore result in aberrant splicing of DNA2. This was confirmed 
experimentally using another minigene assay (Fig. 2E). Here, the c.74+4A>C 
mutant exhibited two RT-PCR products that corresponded to correctly spliced 
and incorrectly spliced transcript lacking canonical exon 1, respectively. 
Nevertheless, as a result of residual levels of correct splicing for both the 












c.74+4A>C and c.1764-38_1764-37ins(53) variants, low levels of wildtype 
transcript and protein would still be produced, in keeping with DNA2 function 
being essential for mammalian development (Lin et al., 2013). 
Lastly, patient P3, who has the most severe reduction in height and the 
smallest head circumference (Supp. Table S1), was found to be compound 
heterozygous for the same c.74+4A>C variant in trans with a missense 
variant, c.1963A>G (p.Thr655Ala, p.T655A). P2 and P3 were phenotypically 
similar and not knowingly related, thus providing additional evidence to 
support pathogenicity of the c.74+4A>C variant. Likewise, there was strong 
evidence for the pathogenicity of the p.T655A substitution: the CADD score 
was 28.2, and given that threonine residue 655 is conserved to yeast and 
forms part of the ATP-binding motif of the DNA2 helicase/translocase domain 
(Fig. 1A, Fig. 2F), it was likely to be functionally critical. Furthermore, 
substitution of the neighboring lysine 654 residue (corresponding to lysine 671 
in older literature based on previous nomenclature) abolishes DNA2 ATPase 
activity, reducing the speed of ssDNA degradation (Levikova et al., 2017; 
Masuda-Sasa, Imamura, & Campbell, 2006). Therefore substitution of the 
adjacent p.T655 might also be expected to affect hydrolysis of ATP, reducing 
the rate of translocation of DNA2 along DNA, consequently diminishing 
nuclease-dependent degradation of ssDNA, and negatively impacting on DNA 
end resection. To investigate this possibility further, the crystal structure of 
mouse DNA2 (80% overall sequence identity to human DNA2; 100% in the 
ATP-binding motif) bound to the ATP hydrolysis product, ADP, (Zhou, 
Pourmal, & Pavletich, 2015) was examined. 












Molecular modelling of the p.T656A variant (the mouse equivalent of 
human p.T655A) with FoldX (Guerois, Nielsen, & Serrano, 2002; 
Schymkowitz et al., 2005) predicted a negligible effect of the variant on 
intramolecular protein stability (ΔΔG = -0.15 kcal/mol). However, the affected 
threonine residue forms substantial intermolecular contacts with ADP, burying 
25.1 Å2 of solvent-accessible surface area, supporting modulation of this 
interaction as the basis for pathogenicity of this substitution. Notably, analysis 
with mCSM-lig (Pires, Blundell, & Ascher, 2016) predicted that the p.T656A 
variant weakens the interaction with ADP (by ~20%). This change in affinity 
would be expected to reduce DNA2 helicase activity and processivity. 
However, as the DNA2 structure does not contain the magnesium 
divalent cation required for ATPase activity, we next examined homologous 
structures that contained both Mg2+ and ADP. For this we used crystal 
structures of human UPF1 (Chakrabarti et al., 2011) and Saccharomyces 
cerevisiae SEN1 helicases (Leonaite et al., 2017), both of which are highly 
homologous to DNA2 around the ATP-binding site, at the amino acid and 
structural level (Supp. Fig. S1A,B). Here, a substantially stronger reduction in 
ADP binding affinity as a result of the threonine to alanine change was 
predicted (2.6 to 3.1-fold), likely due to contacts between the threonine 
residue and Mg2+ at the ATPase site (Supp. Fig. S1B,C). Furthermore, 
molecular modelling of substitutions at the adjacent lysine residue predicted 
these to similarly weaken the interaction with ADP (Supp. Fig. S1C). Notably, 
substitution of this lysine residue in DNA2 has previously been shown to 
abrogate ATPase activity (Levikova et al., 2017; Masuda-Sasa et al., 2006). 
Therefore, while structural modelling of mutational effects on protein-ligand 












interactions has limitations, this molecular modelling, in conjunction with the 
direct physical contact of this threonine residue with ADP/Mg2+, suggests that 
p.T655A negatively affects cellular DNA2 enzyme function in the same 
manner as p.K654E/R, reducing processivity during DNA end resection. 
Our identification of four unrelated patients with biallelic DNA2 variants 
provides strong genetic evidence for DNA2 as an MPD-disease gene. As 
such, this substantively confirms the conclusions of Shaheen et al., who 
reported the homozygous c.3114+6delC intronic DNA2 variant, found within a 
region of homozygosity, as the likely cause of Seckel syndrome in an 
extended consanguineous Saudi Arabian family (Shaheen et al., 2014). The 
term ‘Seckel syndrome’ has frequently been employed to describe patients 
with a sloping forehead, prominent nose and intellectual disability, alongside 
disproportionate microcephaly (Hall, Flora, Scott, Pauli, & Tanaka, 2004; 
Kalay et al., 2011; Majewski, Goecke, et al., 1982). Individuals from the 
originally reported family were reported as having ‘Seckel-like’ facies 
(Shaheen et al., 2014); however, our cases do not have such an appearance. 
Consequently, we suggest employing the broader term ‘MPD’ to categorise 
the phenotype of individuals with biallelic DNA2 variants. 
Heterozygous missense variants in DNA2 have been associated with 
mitochondrial myopathy, with adult-onset autosomal dominant progressive 
external ophthalmoplegia and mitochondrial DNA deletions type 6 (PEOA6) 
(Ronchi et al., 2013). The level of DNA2 deficiency could account for the very 
different phenotype from that described here. Severe depletion arising from 
biallelic variants impairing nuclear genome replication and DNA repair would 
then cause MPD. Marked impairment in cellular DNA2 activity in MPD, 












resulting from both non-coding and coding DNA2 variants, would be 
consistent with the necessity of adequate DNA2 protein levels during 
embryonic development, particularly during rapid cell proliferation, with a 
disruption in timely nuclear DNA replication/repair leading to fewer cells being 
generated, resulting in a smaller individual. In contrast, haploinsufficiency 
would be developmentally tolerated, but in the long term could result in 
mitochondrial DNA depletion and adult-onset myopathy. 
However, a simple model of differing levels of deficiency is difficult to 
reconcile with the lack of any features associated with mitochondrial disease 
in any of the six individuals with biallelic variants in DNA2 (our study and 
Shaheen et al., 2014) or their carrier parents. This argues against a simple 
DNA2 ‘dosage-effect’ model to account for distinct mitochondrial and growth 
phenotypes. Furthermore, heterozygous DNA2 truncating variants appear to 
be tolerated in the general population (gnomAD; Lek et al., 2016). Such 
population data seemingly runs counter to two case reports associating 
truncating variants with childhood myopathy (Chae et al., 2015; 
Phowthongkum & Sun, 2017), however both studies failed to assess parental 
variant status or demonstrate mitochondrial DNA deletions, rendering their 
findings inconclusive. Therefore, as proposed by Shaheen et al., the PEOA6 
DNA2 variants (Ronchi et al., 2013) may instead have an allele-specific effect. 
The biochemical findings of Ronchi et al were most consistent with decreased 
nuclease activity, whereas the p.T655A variant we identified in the helicase 
domain is expected to specifically impair end resection activity of DNA2 
(Daley et al., 2017). This raises the possibility that differing functional 
consequences on this multi-functional enzyme could account for the different 












phenotypic outcomes in MPD and PEOA6. Notably, variants in RBBP8, which 
encodes CtIP, another DNA end resection factor, also lead to MPD (Qvist et 
al., 2011). 
In conclusion, our findings in conjunction with the work of Shaheen et 
al., establish DNA2 as an MPD gene. Future studies will be important to 
establish the molecular and cellular basis for the differing phenotypes of 
PEOA6-DNA2 and MPD-DNA2, with ascertainment of further cases, 
derivation of patient cell lines and development of relevant animal models, 
important to distinguish between potential disease mechanisms. 
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Figure 1. Identification of biallelic DNA2 variants in microcephalic 
primordial dwarfism patients.  
A: DNA2 variants c.74+4A>C, c.1764-38_1764-37ins(53) and c.1963A>G 
(p.Thr655Ala, p.T655A) identified in four MPD patients are indicated in red on 
a schematic of the DNA2 gene (NM_001080449.2), with the previously 
reported c.3114+6delC variant (Shaheen et al., 2014) shown in grey. Key 
domains and motifs are indicated on a cartoon model of the DNA2 protein 
(NP_001073918) structure. 
B: Sanger sequencing chromatograms demonstrating DNA2 variants (marked 
in red) in MPD patients. 
C: Affected individuals exhibit extreme reduction in birth weight, postnatal 
height and OFC, reflecting global growth failure of prenatal onset and extreme 
microcephaly (this study: P1-P4; Shaheen et al., 2014: PD_F6-II:5, PD_F6-
III:1). Measurements plotted as Z-scores (standard deviation, SD, of 
measurement from population mean for age and sex). Black bars represent 
the mean. 
D: Photographs of P1. Written consent to publish photographs was obtained 
from the family. 
 












Figure 2. Transcriptional and structural consequences of DNA2 variants 
identified in MPD patients. 
A: RHCglo minigene reporter constructs used in the minigene splicing assay 
to assess the effect of the DNA2 c.1764-38_1764-37ins(53) variant. A positive 
control for splicing disruption was generated by introducing a point mutation, 
abolishing the acceptor splice site of DNA2 intron 11. Arrows indicate primers 
used for RT-PCR analysis. 
B: c.1764-38_1764-37ins(53) affects splicing of DNA2 transcript. HeLa cells 
were transfected with minigene constructs, followed by RNA extraction, cDNA 
generation and RT-PCR analysis to assess DNA2 splicing patterns. RT-PCR 
products amplified from the HeLa cDNA of the minigene assay samples using 
F and R primers (see panel a) were separated by agarose gel 
electrophoresis. Sanger sequencing analysis of cloned PCR products 
revealed that the product with higher electrophoretic mobility represents 
transcript lacking exon 12, and the lower mobility product the correctly spliced 
transcript. 
C: The splicing defect caused by DNA2 c.1764-38_1764-37ins(53) is also 
detected in patient (P1) PBLs. PCR was performed using primers located in 
exon 11 and exon 13 of DNA2 (indicated by short black arrows) products 
using cDNA generated from minigene assay samples and from RNA extracted 
from P1 peripheral blood. Agarose gel electrophoresis and Sanger 
sequencing analysis of PCR products recapitulated the previous findings. 
D: Sanger electropherograms demonstrate that the c.1764-38_1764-
37ins(53) variant results in skipping of DNA2 exon 12. 
E: Top: RHCglo minigene reporter constructs used in the minigene splicing 
assay to assess the effect of the DNA2 c.74+4A>C variant. As a control, the 
c.74+1G>A point mutation was introduced, abolishing the acceptor splice site 
of DNA2 intron 1. Bottom: DNA2 c.74+4A>C variant affects splicing of DNA2 
transcript. PCR products amplified from HeLa cDNA of the minigene assay 
samples were separated by agarose gel electrophoresis. Sanger sequencing 
analysis of cloned PCR products revealed that the product with higher 












electrophoretic mobility represents transcript lacking exon 1 and the lower 
mobility product the correctly spliced transcript. 
F: DNA2 threonine 655, mutated in MPD patient P3, is a highly conserved 
residue in the ATP binding motif (boxed in green) within the 
helicase/translocase domain. Alignment generated and visualised using 
Jalview multiple sequence alignment software (Waterhouse, Procter, Martin, 
Clamp, & Barton, 2009). 
G: DNA2 p.K654 and p.T655 are important for ATP/ADP binding. Top: DNA2 
protein domains (N-terminus, nuclease and helicase/translocase) are 
represented in different colours (PDB ID: 5EAW; (Zhou et al., 2015)). ADP is 
shown in cyan spheres; p.T655, shown in red, indicates mouse DNA2 p.T656 
(the equivalent of human p.T655). Below: this threonine residue contacts 
ADP, similar to p.K654 (p.K655 in mouse, indicated in blue = p.K654 in 
human DNA2). Substitution of K654 abolishes DNA2 ATPase activity. 
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